Alys Pharmaceuticals, a company specializing in immuno-dermatological treatments, has launched with $100 million in financing from Medicxi. The company offers a pipeline of programs covering inflammatory diseases, autoimmune diseases, dermatology-supportive care for cancer patients and rare dermatoses.
Alys combines the assets and platforms of six Medicxi companies, including Aldena Therapeutics, Graegis Pharmaceuticals and Granular Therapeutics, among others. Its programs focus on indications including mastocytosis and cutaneous T-cell lymphoma.
The company collaborates with institutions such as UMass Chan Medical School and the Icahn School of Medicine at Mount Sinai on research and development. Over the next three years, Alys aims to deliver between seven to ten clinical proof-of-concept readouts and potentially advance at least one program to registrational studies.
